Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Keros Therapeutics, Inc. | CHIEF EXECUTIVE OFFICER, Director | Common Stock | 253K | $11.5M | $45.29 | Apr 8, 2023 | Direct |
Keros Therapeutics, Inc. | CHIEF EXECUTIVE OFFICER, Director | Employee Stock Option (right to buy) | 125K | Feb 23, 2024 | Direct | ||
Eloxx Pharmaceuticals, Inc. | Director | Stock Options (Right to Buy) | 20K | Jun 15, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KROS | Keros Therapeutics, Inc. | Feb 23, 2024 | 1 | $0 | 4 | Feb 23, 2024 | CHIEF EXECUTIVE OFFICER, Director |
KROS | Keros Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4 | Feb 15, 2024 | CHIEF EXECUTIVE OFFICER, Director |
KROS | Keros Therapeutics, Inc. | Apr 8, 2023 | 2 | $1.92K | 4 | Apr 11, 2023 | Chief Executive Officer, Director |
KROS | Keros Therapeutics, Inc. | Feb 16, 2023 | 1 | $0 | 4 | Feb 17, 2023 | Chief Executive Officer, Director |
ELOX | Eloxx Pharmaceuticals, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director |
KROS | Keros Therapeutics, Inc. | Jun 9, 2022 | 2 | $1.5K | 4 | Jun 10, 2022 | Chief Executive Officer, Director |
KROS | Keros Therapeutics, Inc. | Jan 21, 2022 | 1 | $0 | 4 | Jan 25, 2022 | Chief Executive Officer, Director |
ELOX | Eloxx Pharmaceuticals, Inc. | May 19, 2021 | 1 | $0 | 4 | May 20, 2021 | Director |